X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on December 2, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 396,824 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
波士頓，2024年12月3日（環球新聞社）-- x4製藥（納斯達克股票代碼：XFOR）是一家致力於改善罕見免疫系統疾病患者生活的公司，今天宣佈，自2024年12月2日起，該公司根據x4製藥公司2019年引誘性股權激勵計劃（"2019引誘性計劃"）向新員工發放引誘性獎勵。2019引誘性計劃專門用於向以前不是x4員工的個人授予股權獎勵。引誘性獎勵包括購買x4普通股396,824股的期權。這些股票獎勵是作爲對新員工與x4簽訂就業協議的誘因而授予的，符合納斯達克上市規則5635（c）（4）的規定，並已獲得x4董事會薪酬委員會的批准。
The options have a ten-year term and an exercise price of $0.371 per share, which is equal to the closing price of X4's common stock on December 2, 2024. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee's continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.
這些期權有十年期限，行權價格爲每股0.371美元，與2024年12月2日x4普通股的收盤價相同。每個期權將在四年內分批授予，其中25%的股份將在12個月後獲得，其餘股份將在接下來的36個月內每月獲得，前提是員工在這些獲權日期繼續與x4合作。這些期權受2019年引誘性計劃的條款和條件以及涵蓋授予的獎勵協議的條款和條件約束。
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at .
關於x4製藥
X4製藥正在爲罕見免疫系統疾病患者提供進展，並開發和推廣創新治療方案，以滿足他們的重大未滿足需求。利用我們在CXCR4和免疫系統生物學方面的專業知識，我們已成功開發了mavorixafor，並在其第一個適應症中獲得了美國批准 - XOLREMDI（mavorixafor）膠囊。我們還在評估mavorixafor在其他潛在適應症中的使用。X4製藥的總部位於美國馬薩諸塞州波士頓，研究中心位於奧地利維也納。欲了解更多信息，請訪問我們的網站。
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
公司聯繫人：
Jose Juves
企業和患者事務負責人
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
投資者聯繫人：
Daniel Ferry
LifeSci Advisors董事總經理
daniel@lifesciadvisors.com
(617) 430-7576
Source: X4 Pharmaceuticals
資料來源：X4 Pharmaceuticals
